Andreessen Horowitz led the Series A round to support product development and network growth.
"A CV is a poor proxy for what someone is truly capable of. Ethos helps people to see the full shape of their expertise and where it fits in an AI-transformed economy – acting as their agent, opening doors they didn’t know existed, and giving companies a far more precise way to find the people they actually need. AI is reshaping the labour market faster than our tools for valuing human expertise can keep up. Ethos is built to change that,"
General Catalyst led the equity portion of the £69m investment, which also features a debt facility from Trinity Capital.
"We have crossed 10,000 properties under management, placing Dwelly among the UK’s top 15 largest letting agencies in less than 2 years – an unseen speed of growth for letting agencies. Our vision is to build an end-to-end platform evolving into a fully transactional rental marketplace with a robust fintech layer for rent collection and ancillary products."
The seed round was co-led by Ten Eleven Ventures and General Catalyst.
"There’s no established playbook for how to deploy agentic AI now. Many times, the limited visibility and lack of understanding of potential risks are key blockers for many CISOs and technology leaders. Geordie supports these leaders so that organizations can bring strategic innovation in-house confidently and regain control of their rapidly changing technology environment. The security Geordie brings will be a critical part of safely embracing the agentic AI revolution destined for the decade ahead."
General Catalyst led the seed financing to accelerate the development of Portia AI's open source developer framework and cloud platform.
"AI engineers with deep expertise painstakingly navigate their way through the challenges of deploying reliable agents in production, but we want to democratise the solutions for all developers,"
General Catalyst led the financing alongside a syndicate of new and existing investors to support the developer of antibody-based therapeutics.
"KnotBodies represent a potential breakthrough biologic drug modality, delivering greater potency, selectivity, and durability. We believe they will provide transformational new therapeutic options for ion channel- and GPCR-driven diseases across a wide range of therapeutic areas with a remaining high unmet medical need. The calibre of our international investor syndicate validates our approach, and I would like to welcome our new investors to Maxion and thank our existing investors for their continued support."
